Mesa Labs Q1 Revenue Edges Up 1%, Adjusted Operating Income Jumps 19.5%
MLAB sits 73% above its 52-week low of $58.834.
Summary
Mesa Labs reported fiscal Q1 revenue of approximately $62.8 million, a 1% year-over-year increase, driven by its Calibration Solutions and Biopharmaceutical Development divisions. Adjusted operating income excluding unusual items rose 19.5%, reflecting improved gross margins in three of four divisions from favorable product mix and supply chain efficiencies. However, net income fell 40.3% due to higher nonoperating expenses, and the Sterilization and Disinfection Control unit saw a revenue decline tied to fulfillment challenges. The company plans to provide full-year guidance in November alongside first-half results, leaving near-term visibility limited. This follows a strong fiscal 2026 turnaround reported in May, and the mixed Q1 performance suggests uneven recovery across segments.
At the time of this announcement, MLAB was trading at $101.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $568.7M. The 52-week trading range was $58.83 to $113.99. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.